Mayland Chang

Mayland Chang


Dr. Chang obtained B.S. degrees in biological sciences and chemistry from the University of Southern California, and a Ph.D. in chemistry from the University of Chicago.  Subsequently, she conducted postdoctoral research at Columbia University as a National Institutes of Health postdoctoral fellow.  She joined the faculty of the University of Notre Dame in 2003.  Previously, Dr. Chang was Chief Operating Officer of University Research Network, Inc., Senior Scientist with Pharmacia Corporation, and Senior Chemist at Dow Chemical Company.  She has characterized the ADME properties of numerous drugs, as well as prepared NDAs, INDs, Investigator's Brochures, product development plans, and candidate drug evaluations. 

Research Interests

The Chang lab conducts biomedical research to understand the molecular basis of disease and to design small molecules for therapeutic intervention. Some of our current projects are:

Chronic wounds are a complication of diabetes that results in >70,000 lower-limb amputations in the United States every year. The reasons why diabetic wounds are recalcitrant to healing are not fully understood. There is a single FDA-approved drug to treat diabetic foot ulcers; however, it is associated with increased mortality and cancer. We used an affinity resin that binds only the active forms of MMPs (matrix metalloproteinase) and related ADAMs (a disintegrin and metalloproteinase) coupled with quantitative proteomics to identify active MMP-8 and MMP-9 in diabetic wounds. Using the selective MMP-9 inhibitor ND-336 led to acceleration of wound healing by lowering inflammation, enhancing angiogenesis, and re-epitheliazation of the wound, thereby reversing the pathological condition. The role of MMP-9 was confirmed with diabetic MMP-9-knockout mice. Furthermore, the beneficial role MMP-8 in wound healing was determined with a selective MMP-8 inhibitor and by topical application of the proteinase MMP-8. The combined topical application of ND-336 (a small molecule) and active recombinant MMP-8 (an enzyme) enhanced healing even more, in a strategy that holds condiserable promise in healing of diabetic wounds. We are currently identifying and quantifying active MMPs in patients with diabetic foor ulcers.

Another project involves the design, syntheses, and evaluation of novel antibiotics to treat methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff.) infections. We have identified novel classes of antibacterials. The quinazolinones are active in vivo against MRSA and have an unprecedented mechanism of action, binding to the allosteric site of PBP2a and triggering conformational changes that result in opening of the active site of PBP2a. The oxadiazoles are bactericidal, exhibit efficacy comparable or better to that of linezolid in mouse peritonitis and neutropenic thigh models of infection, have excellent pharmacokinetic properties, synergize with β-lactam antibiotics, and exhibit a long postantibiotic effect. We are currently optimizing the oxadiazoles to impart in vivo C. diff. activity. 

Recent Papers

  • Janardhanan, J.; Meisel, J.E.; Ding, D.; Schroeder, V.A.; Wolter, W.R.; Mobashery, S.; Chang, M. "In Vitro and In Vivo Synergy of the Oxadiazole Class of Antibacterials with β-Lactams" Antimicrob. Agents Chemother. 2016, 60(9), 5581-5588.
  • Bouley, R.; Ding, D.; Peng, Z.; Bastian, M.; Lastochkin, E.; Song, W.; Suckow, M.A.; Schroeder, V.A.; Wolter, W.R.; Mobashery, S.; Chang, M. "Structure-Activity Relationship for the 4(3H)-Quinazolinone Antibacterials" J. Med. Chem. 2016, 59, 5011-5021.
  • Chang, M. "Restructuring of the Extracellular Matrix in Diabetic Wounds and Healing: A Perspective" Pharmacol. Res. 2016, 107, 243-248.
  • Lee, M; Chen, Z.; Tomlinson, B.N.; Gooyit, M.; Hesek, D.; Juarez, M.R.; Nizam, R.; Boggess, B.; Lastochkin, E.; Schroeder, V.A.; Wolter, W.R.; Suckow, M.A.; Cui, J.; Mobashery, S.; Gu, Z.; Chang, M. "Water-Soluble MMP-9 Inhibitor Reduces Lesion Volume after Severe Traumatic Brain Injury" ACS Chem. Neurosci. 2015, 6, 1658-1664.
  • Gao, M.; Nguyen, T.T.; Suckow, M.A.; Wolter, W.R.; Gooyit, M.; Mobashery, S.; Chang, M. "Acceleration of Diabetic Wound Healing Using a Novel Protease-Anti-Protease Combination Therapy" Proc. Nat. Acad. Sci.  2015, 112, 15226-15231.
  • Gooyit, M.; Peng, Z.; Wolter, W.R.; Pi, H.; Ding, D.; Hesek, D.; Lee, M.; Boggess, B.; Champion, M.M.; Suckow, M.A.; Mobashery, S.; Chang, M. "A Chemical Biological Strategy to Facilitate Diabetic Wound Healing" ACS Chem. Biol. 2014, 9, 505-510.

Contact Information

  • Research Professor; Director, Chemistry-Biochemistry-Biology Interface (CBBI) Program
  • Office: 354C McCourtney
  • Phone: (574) 631-2965
  • Send an email

Primary Research Areas

Research Specialties